Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 2,700,000 shares, a drop of 5.6% from the December 15th total of 2,860,000 shares. Currently, 7.6% of the company’s shares are sold short. Based on an average daily trading volume, of 223,000 shares, the days-to-cover ratio is currently 12.1 days.
NASDAQ:AMPH traded down $0.02 during mid-day trading on Thursday, hitting $20.01. The company had a trading volume of 59,462 shares, compared to its average volume of 195,620. The business has a fifty day simple moving average of $19.16 and a 200-day simple moving average of $19.96. The company has a current ratio of 3.11, a quick ratio of 1.84 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a 1 year low of $16.71 and a 1 year high of $25.43. The firm has a market capitalization of $948.66 million, a price-to-earnings ratio of 95.29 and a beta of 1.16.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. Amphastar Pharmaceuticals had a return on equity of 5.07% and a net margin of 15.77%. The company had revenue of $80.14 million for the quarter, compared to analyst estimates of $78.53 million. During the same period last year, the company posted $0.12 earnings per share. The firm’s revenue was up 6.1% compared to the same quarter last year. As a group, research analysts anticipate that Amphastar Pharmaceuticals will post 0.05 earnings per share for the current year.
Several research analysts recently weighed in on AMPH shares. TheStreet lowered Amphastar Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, November 7th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. BidaskClub lowered Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 8th. Finally, ValuEngine raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $24.05.
In related news, General Counsel Jason B. Shandell sold 25,000 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $18.44, for a total value of $461,000.00. Following the transaction, the general counsel now directly owns 163,898 shares of the company’s stock, valued at approximately $3,022,279.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jason B. Shandell sold 8,205 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $19.13, for a total value of $156,961.65. Following the completion of the transaction, the general counsel now directly owns 138,898 shares in the company, valued at $2,657,118.74. The disclosure for this sale can be found here. Insiders sold a total of 35,205 shares of company stock worth $656,467 over the last ninety days. Corporate insiders own 30.80% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Millennium Management LLC increased its position in shares of Amphastar Pharmaceuticals by 266.3% during the third quarter. Millennium Management LLC now owns 54,180 shares of the company’s stock worth $1,074,000 after acquiring an additional 39,389 shares during the last quarter. California State Teachers Retirement System grew its stake in Amphastar Pharmaceuticals by 1.2% in the third quarter. California State Teachers Retirement System now owns 55,912 shares of the company’s stock worth $1,109,000 after purchasing an additional 668 shares in the last quarter. Voya Investment Management LLC grew its stake in Amphastar Pharmaceuticals by 3,731.0% in the third quarter. Voya Investment Management LLC now owns 603,377 shares of the company’s stock worth $11,965,000 after purchasing an additional 587,627 shares in the last quarter. First Trust Advisors LP grew its stake in Amphastar Pharmaceuticals by 7.7% in the third quarter. First Trust Advisors LP now owns 124,516 shares of the company’s stock worth $2,469,000 after purchasing an additional 8,942 shares in the last quarter. Finally, California Public Employees Retirement System grew its stake in Amphastar Pharmaceuticals by 58.1% in the third quarter. California Public Employees Retirement System now owns 108,261 shares of the company’s stock worth $2,147,000 after purchasing an additional 39,774 shares in the last quarter. 51.27% of the stock is currently owned by institutional investors.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
See Also: Do You Need a Fiduciary?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.